Q301--VISN 6 Cytopath Biopsy Lab ThyroSeq Genomic Testing
Closed Special Notice Posted
- Solicitation number
- 36C24625Q0876
- Agency
-
Veterans Integrated Service Network 6
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Network Contracting Office 6 (VISN 6) has issued a Special Notice announcing its intent to award a sole source, firm fixed price contract for ThyroSeq v3 Genomic Classifier Testing services. The contract will be awarded to Cytopath Biopsy Lab (CBLPath) located in Rye Brook, New York, to provide molecular testing services for thyroid nodules across seven VA Medical Centers within the VISN 6 region. These medical centers include facilities in Asheville, Durham, Fayetteville, Hampton, Richmond, Salem, and Salisbury. The VA has determined through market research that CBLPath is the authorized service provider for this specialized genomic testing, and using alternative suppliers would result in duplicated costs without recovery through competition. This notice falls under NAICS code 621511 for Medical Laboratories and PSC Q301 for Reference Laboratory Testing.
The primary objective of this sole source contract is to secure high-quality molecular testing services that demonstrate high specificity and sensitivity for malignancy detection in indeterminate thyroid nodules, utilizing an extensive panel of thyroid-related gene mutations. While this is not a request for competitive quotes, the VA will accept written submissions from businesses that believe they can provide equivalent ThyroSeq v3 Genomic Classifier Testing services, with responses due by 10:00 AM EDT on September 4, 2025. Interested contractors must submit comprehensive documentation including company information, contact details, SAM UEI number, manufacturer authorization letters, and sufficient supporting evidence demonstrating their ability to meet the testing requirements. The VA emphasizes that the molecular test must maintain high predictive value and employ comprehensive genetic analysis capabilities to ensure continuity of patient care without unacceptable delays or cost duplication.
Notice text
Special Notice
Special Notice
Page 2 of 2
*= Required Field
Special Notice
Page 1 of 2
NOTICE OF INTENT TO AWARD SOLE SOURCE
The Department of Veterans Affairs, Network Contracting Office (NCO) 6 intends to award a
sole source, firm fixed price contract to Cytopath Biopsy Lab (CBLPath), located at 760 Westchester Ave, Rye Brook, NY, 10573, to provide services for the Thyroseq v3 Genomic Classifier Testing for the VISN (including the Asheville, Durham, Fayetteville, Hampton, Richmond, Salem and Salisbury VA Medical Centers). It is the Government s belief that the proposed candidate is the authorized service provider of the services for the Thyroseq v3 Genomic Classifier Testing. The molecular test used for evaluating indeterminate thyroid nodules should have high specificity and sensitivity for malignancy, high predictive value, and should employ an extensive panel of thyroid-related gene mutations for detection. Using any other supplier would result in duplicated costs that would not be recovered through competition.
This notice of intent is not a request for competitive quotes. Market research has determined that these items can only be obtained from a single source without an unacceptable duplication of cost or delay in the continuity of patient care. No solicitation documents are available, and telephone requests will not be accepted.
However, any business that believes it can provide the services for the Thyroseq v3 Genomic Classifier Testing for molecular testing on Thyroid nodules may give written notice to lakeva.cousins@va.gov, by 10:00am EDT on September 4, 2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to comply with the above requirement. Interested and capable respondents are requested to provide the information below.
All responses to this notice shall include: company name, address, point of contact, phone number, System for Award (SAMs) Unique Entity Id Number (UEI), manufacturer authorization letter, authorized dealer, authorized distributor, or authorized reseller documentation.
Responses will be considered by the Government; however, a determination by the Government
not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government.
NAICS Code: 621511 Medical Laboratories
PSC: Q301 Medical Reference Laboratory Testing
Files
| File | Type | Posted |
|---|---|---|
| 36C24625Q0876.docx | DOCX document |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Q301--FY27 (BASE+4) STAT Laboratory Testing - Syracuse (VA-27-00010334) | Veterans Integrated Service Network 2 | No set-aside | |
| Q301--NEW – STX Specialized Molecular Residual Disease Testing | Veterans Integrated Service Network 17 | No set-aside | |
| Q301--Reference Laboratory Testing | Veterans Integrated Service Network 2 | No set-aside | |
| 6550--Cepheid GeneXpert Testing Supplies | Veterans Integrated Service Network 5 | No set-aside | |
| NWI Offsite Pathology Services | Veterans Integrated Service Network 23 | Total Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity